- Price:
- $8.82
- Open:
- $8.83
- Previous close:
- $8.77
- Day's range:
- $8.66 - $8.89
- Year's range:
- $3.53 - $23.86
- Net Income per Share:
- -2.18
- Price-to-Earnings ratio:
- -4.05
- 52-week Price Range:
- $9.92
- Volume:
- $1,906,070.00
- Average volume:
- $6,127,414.00
Company profile for Novavax, Inc.
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company’s vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
- Stock exchanges:
- NASDAQ
- Sector:
- Healthcare
- Industries:
- Biotechnology
- Ticker:
- NVAX
- CIK:
- 1000694
- ISIN:
- US6700024010
- Website:
- https://www.novavax.com
- Phone:
- 240 268 2000
- Origin:
- United States
- Employees:
- 1,541